Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

The Proposal Enterprise Value therefore closely reflects the value that Royalty Pharma is ascribing to the Tysabri Royalty.

Royalty Pharma's calculation framework, analysis and assumptions, derived from publicly available information, are contained in Appendix IV.

Elan will have little or no strategic value following the Tysabri Transaction Following the completion of the Tysabri Transaction, Royalty Pharma believes that the field of likely acquirors of Elan will have narrowed sharply.

Royalty Pharma does not believe that pharmaceutical or biotech companies would be interested in acquiring Elan given that its material assets (in the context of the assets of the Elan Group, taken as a whole), following the completion of the Tysabri Transaction, will consist of cash and the Tysabri Royalty. As such, Royalty Pharma believes that the only companies that would be interested in acquiring Elan would be financial buyers. As the world's largest investor in pharmaceutical royalties, Royalty Pharma believes that it may be the only credible buyer capable of acquiring the whole of Elan.

Conclusion: the choice for Elan Shareholders is clearRoyalty Pharma's Proposal provides a clear choice for Elan Shareholders:

  • Receive what Royalty Pharma believes is the full value for Elan Stock now, in cash; or
  • Trust that Elan's acquisition strategy will succeed by remaining invested in a company with two material assets: a royalty interest in Tysabri and cash, the majority of which Elan has stated will be used for acquisitions.
  • IF ELAN SHAREHOLDERS SUPPORT THE ROYALTY PHARMA PROPOSAL, THEN THEY SHOULD ENCOURAGE THE BOARD OF ELAN TO ENGAGE WITH ROYALTY PHARMA.ELAN SHAREHOLDERS MAY NEVER GET ANOTHER OPPORTUNITY TO MAKE THIS CHOICE. Further information on Royalty PharmaRoyalty Pharma is a private entity founded in 1996 and is the investment manager to entities investing in royalty interests in marketed and late stage biopharmaceutical
    '/>"/>

    SOURCE RP Management, LLC
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

    Related biology technology :

    1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
    2. Cowen Healthcare Royalty Partners Raises $1 Billion
    3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
    4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
    5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
    6. AVANIR Pharmaceuticals To participate in two conferences in March
    7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
    8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
    9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
    10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
    11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... NY (PRWEB) September 18, 2014 Whitehouse ... negotiations with Salem Realty Group and has acquired an ... space within the Salem Executive Complex adjacent to its ... was held on Friday September 5th. Whitehouse Labs is ... the entire space specifically for package testing. The prime ...
    (Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
    (Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... publication of another peer-reviewed clinical study.    ... Multi-center Randomized Controlled Clinical Trial Evaluating the Use ... Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression ...
    (Date:9/17/2014)... 17, 2014 Immunomic Therapeutics, Inc. announced ... (SBIR) grant to support the continued preclinical development of ... with approximately $255,000 over one year to conduct vaccine ... food allergy, affect over one million Americans and are ... Tree nut exposure is also a risk for peanut ...
    Breaking Biology Technology:Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3
    ... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... for 2011, highlighting its continued focus on strong ... Company,s diabetes franchise, notably through advancing the investigational ... other value-driving development programs. Daniel M. Bradbury, president ...
    ... BioLife Solutions, Inc. (OTC Bulletin Board: BLFS ) ... and Chief Executive Officer Mike Rice, to summarize the continued ... strategic growth initiatives.   (Logo:   http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) ... of $575,000 for the fourth quarter of 2010, an increase ...
    ... The Jackson Laboratory (JAX), Sackler School of Graduate Biomedical Sciences ... a new mammalian genetics track for Ph.D. students. The joint ... and Tufts. Combining the faculty and resources of the genetics ... the faculty and resources at JAX, with its emphasis on ...
    Cached Biology Technology:Amylin to Advance Key Value-Driving Opportunities in 2011 2Amylin to Advance Key Value-Driving Opportunities in 2011 3BioLife Solutions CEO Issues 2010 Corporate Update 2BioLife Solutions CEO Issues 2010 Corporate Update 3The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 2The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 3
    (Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
    (Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
    (Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
    Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
    ... is available in German . , ... , is able to rapidly ,and efficiently detoxify chemical ... the Tokyo subway attacks in 1995. A detailed understanding ... is ,necessary for efforts aiming to improve their properties. ...
    ... of Canada,s southern Rockies are a more distinct breed ... by University of Calgary researchers that is shedding light ... In a study published in the current issue of ... Design PhD candidate Byron Weckworth and his research group ...
    ... release is available in French . ... is pleased to announce that Concordia,s Centre for Structural ... research done by nine universities which are part of ... focusing on the conversion of agricultural waste into biofuel ...
    Cached Biology News:Structure of enzyme against chemical warfare agents determined 2Mountain caribou's ancient ancestry revealed 2
    ... offers major advantages over other RNA precipitation methods ... or carbohydrates. It is the method of choice ... from RNA preparations. Note, LiCl precipitation may not ... If the RNA is to be used for ...
    ... Antifade Kit is an aqueous-based mounting reagent ... dyes. This formulation of antifade minimizes the ... Blue fluorophores that is often seen with ... available with the blue-fluorescent nucleic acid ...
    in vitro Translation, Accessory Products...
    Mouse Collagen IV...
    Biology Products: